Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;21(12):1687-1696.
doi: 10.1016/j.hpb.2019.04.014. Epub 2019 May 29.

Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis

Xiu-Ping Zhang  1 , Zong-Tao Chai  1 , Yu-Zhen Gao  2 , Zhen-Hua Chen  1 , Kang Wang  1 , Jie Shi  1 , Wei-Xing Guo  1 , Teng-Fei Zhou  3 , Jin Ding  3 , Wen-Ming Cong  4 , Dong Xie  5 , Wan Y Lau  6 , Shu-Qun Cheng  7
Affiliations
Free article

Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis

Xiu-Ping Zhang et al. HPB (Oxford). 2019 Dec.
Free article

Abstract

Background: Microvascular invasion (MVI) is a major determinant of survival outcome for hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy of postoperative adjuvant Sorafenib (PA-Sorafenib) in HCC patients with MVI after R0 liver resection (LR).

Methods: The data of patients who underwent R0 LR for HCC with histologically confirmed MVI at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. The survival outcomes for patients who underwent PA-Sorafenib were compared with those who underwent R0 LR alone. Propensity score matching (PSM) analysis was performed.

Results: 728 HCC patients had MVI in the resected specimens after R0 resection, with 581 who underwent LR alone and 147 patients who received in additional adjuvant sorafenib. PSM matched 113 patients in each of these two groups. The overall survival (OS) and recurrence free survival (RFS) were significantly better for patients in the PA-sorafenib group (for OS: before PSM, P = 0.003; after PSM, P = 0.007), (for RFS: before PSM, P = 0.029; after PSM, P = 0.001), respectively. Similar results were obtained in patients with BCLC 0-A, BCLC B and Child-Pugh A stages of disease.

Conclusions: PA-Sorafenib was associated with significantly better survival outcomes than LR alone for HCC patients with MVI.

PubMed Disclaimer

Publication types